Home > Oncology > ASCO 2021 > Letter from the Editor

Letter from the Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch
ASCO 2021
Dear Reader, I am delighted to introduce you to our ASCO 2021 Annual Meeting congress report. Expect plenty of new insights in immunotherapy: checkpoint inhibitors may soon be indicated in (neo)adjuvant treatment, and have become the first anti-neoplastic treatment to provide a benefit in the adjuvant treatment of renal cell carcinoma. New immunologic targets (such as LAG-3) continue to enforce treatment options. You may already have known that toxicity somehow rhymes with treatment efficiency; two studies in checkpoint inhibitors seem to confirm this. Of course, that’s not all there is. HER2 overexpression leads to new treatment options in colorectal cancer. Check out new treatment targets in haematological and solid tumours. The principle of personalised medicine with gene sequencing-based treatment receives further conformation with studies in paediatric cancers. There’s much more in this report – see for yourself! Wary of visio-conferences? ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on